First Horizon Corporation’s Neurocrine Biosciences NBIX Stock Holding History

First Horizon Corporation’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.7K	Hold	123	–	–	﹤0.01%	949
2026 Q1	$16.2K	Buy	123 +12	+11%	+$1.59K	﹤0.01%	946
2025 Q4	$15.7K	Buy	111 +29	+35%	+$4.2K	﹤0.01%	1016
2025 Q3	$11.5K	Buy	+82	New	+$11.1K	﹤0.01%	1037
2021 Q2	$25K	Hold	266	–	–	﹤0.01%	512
2021 Q1	$25K	Sell	266 -6	-2%	-$629	﹤0.01%	501
2020 Q4	$26K	Buy	272 +103	+61%	+$9.95K	﹤0.01%	466
2020 Q3	$16K	Buy	+169	New	+$19.5K	﹤0.01%	538

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

First Horizon Corporation's NBIX Position: Q2 2026 in Review

First Horizon Corporation held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 123 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

First Horizon Corporation first reported a position in NBIX in Q3 2020 and has held it in 8 quarters since. The position peaked at $26K in Q4 2020. 279 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

First Horizon Corporation held 123 shares of Neurocrine Biosciences worth $20.7K as of Q2 2026.
First Horizon Corporation left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #949 holding.
First Horizon Corporation first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 8 quarters since.
First Horizon Corporation's Neurocrine Biosciences position peaked at $26K in Q4 2020.
279 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.